Protagenic Therapeutics, Inc.\new annual r&d spending
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Protagenic Therapeutics, Inc.\new R&D Spending Growth & History (PTIX)
Protagenic Therapeutics, Inc.\new's r&d spending was $901,896 for fiscal 2026.
View full Protagenic Therapeutics, Inc.\new company overviewProtagenic Therapeutics, Inc.\new annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | $901,896 | $525,156 | +139.39% |
| 2025 | 2025-03-31 | $376,740 | — | — |
| 2024 | 2024-12-31 | $3.8M | $781,381 | +25.51% |
| 2023 | 2023-12-31 | $3.1M | $1.5M | +92.77% |
| 2022 | 2022-12-31 | $1.6M | $452,449 | +39.80% |
| 2021 | 2021-12-31 | $1.1M | $436,993 | +62.45% |
| 2020 | 2020-12-31 | $699,797 | −$108,150 | −13.39% |
| 2019 | 2019-12-31 | $807,947 | −$73,239 | −8.31% |
| 2018 | 2018-12-31 | $881,186 | $163,734 | +22.82% |
| 2017 | 2017-12-31 | $717,452 | $299,586 | +71.69% |
| 2016 | 2016-12-31 | $417,866 | −$38,408 | −8.42% |
| 2015 · Dec 31 | 2015-12-31 | $456,274 | — | — |
| 2014 | 2014-06-30 | $42,000 | — | — |
Protagenic Therapeutics, Inc.\new quarterly r&d spending
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q4.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | $109,925 | −$284,187 | −72.11% |
| Q4 2026 | 2026-03-31 | $80,769 | −$799,603 | −90.83% |
| Q3 2026 | 2025-12-31 | $153,786 | $19,206 | +14.27% |
| Q2 2026 | 2025-09-30 | $273,229 | $256,265 | +1510.64% |
| Q1 2026 | 2025-06-30 | $394,112 | $374,977 | +1959.64% |
| Q4 2025 | 2025-03-31 | $880,372 | −$580,374 | −39.73% |
| Q4 2024 | 2024-12-31 | $134,580 | −$785,793 | −85.38% |
| Q3 2024 | 2024-09-30 | $16,964 | −$1.1M | −98.49% |
| Q2 2024 | 2024-06-30 | $19,135 | −$652,034 | −97.15% |
| Q1 2024 | 2024-03-31 | $1.5M | $1.1M | +319.72% |
| Q4 2023 | 2023-12-31 | $920,373 | $662,853 | +257.40% |
| Q3 2023 | 2023-09-30 | $1.1M | $622,664 | +124.19% |
| Q2 2023 | 2023-06-30 | $671,169 | $510,654 | +318.13% |
| Q1 2023 | 2023-03-31 | $348,031 | −$321,807 | −48.04% |
| Q4 2022 | 2022-12-31 | $257,520 | $110,952 | +75.70% |
| Q3 2022 | 2022-09-30 | $501,366 | $244,087 | +94.87% |
| Q2 2022 | 2022-06-30 | $160,515 | $19,923 | +14.17% |
| Q1 2022 | 2022-03-31 | $669,838 | $77,487 | +13.08% |
| Q4 2021 | 2021-12-31 | $146,568 | $104,508 | +248.47% |
| Q3 2021 | 2021-09-30 | $257,279 | −$282,491 | −52.34% |
| Q2 2021 | 2021-06-30 | $140,592 | $88,584 | +170.33% |
| Q1 2021 | 2021-03-31 | $592,351 | $526,392 | +798.06% |
| Q4 2020 | 2020-12-31 | $42,060 | −$474,059 | −91.85% |
| Q3 2020 | 2020-09-30 | $539,770 | $508,617 | +1632.64% |
| Q2 2020 | 2020-06-30 | $52,008 | −$73,256 | −58.48% |
| Q1 2020 | 2020-03-31 | $65,959 | −$69,452 | −51.29% |
| Q4 2019 | 2019-12-31 | $516,119 | $322,280 | +166.26% |
| Q3 2019 | 2019-09-30 | $31,153 | −$131,918 | −80.90% |
| Q2 2019 | 2019-06-30 | $125,264 | −$208,598 | −62.48% |
| Q1 2019 | 2019-03-31 | $135,411 | −$55,003 | −28.89% |
| Q4 2018 | 2018-12-31 | $193,839 | −$114,002 | −37.03% |
| Q3 2018 | 2018-09-30 | $163,071 | $12,452 | +8.27% |
| Q2 2018 | 2018-06-30 | $333,862 | $213,682 | +177.80% |
| Q1 2018 | 2018-03-31 | $190,414 | $51,602 | +37.17% |
| Q4 2017 | 2017-12-31 | $307,841 | — | — |
| Q3 2017 | 2017-09-30 | $150,619 | $39,798 | +35.91% |
| Q2 2017 | 2017-06-30 | $120,180 | −$170,397 | −58.64% |
| Q1 2017 | 2017-03-31 | $138,812 | $90,297 | +186.12% |
| Q3 2016 | 2016-09-30 | $110,821 | −$92,993 | −45.63% |
| Q2 2016 | 2016-06-30 | $290,577 | $250,602 | +626.90% |
| Q1 2016 · Mar 31 | 2016-03-31 | $48,515 | $27,066 | +126.19% |
| Q4 2015 | 2015-12-31 | $191,036 | $191,036 | — |
| Q1 2016 · Sep 30 | 2015-09-30 | $203,814 | $203,814 | — |
| Q4 2015 · Jun 30 | 2015-06-30 | $39,975 | $26,975 | +207.50% |
| Q3 2015 | 2015-03-31 | $21,449 | $13,449 | +168.11% |
| Q2 2015 | 2014-12-31 | $0 | −$10,000 | — |
| Q1 2015 | 2014-09-30 | $0 | −$11,000 | — |
| Q4 2014 | 2014-06-30 | $13,000 | — | — |
| Q3 2014 | 2014-03-31 | $8,000 | — | — |
| Q2 2014 | 2013-12-31 | $10,000 | — | — |
| Q1 2014 | 2013-09-30 | $11,000 | — | — |
Protagenic Therapeutics, Inc.\new r&d spending trends
Between the periods ended 2014-06-30 and 2026-03-31, Protagenic Therapeutics, Inc.\new's r&d spending increased from $42,000 to $901,896, a change of $859,896. The latest reported quarter, Q1 2027, shows $109,925.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Protagenic Therapeutics, Inc.\new source filings ↗